|
業務類別
|
Biotechnology |
|
業務概覽
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders. |
| 公司地址
| 99 High Street, 30th Floor, Boston, MA, USA, 02110 |
| 電話號碼
| +1 617 300-8460 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.praxismedicines.com |
| 員工數量
| 168 |
| Mr. Marcio Souza |
Director, President and Chief Executive Officer |
美元 640.00K |
19/02/2026 |
| Mr. Timothy E. Kelly |
Chief Financial Officer |
美元 511.50K |
19/02/2026 |
| Ms. Lauren Mastrocola |
Principal Accounting Officer |
-- |
19/02/2026 |
| Mr. Alex Nemiroff, J.D. |
General Counsel and Secretary |
美元 442.94K |
19/02/2026 |
| Ms. Megan Sniecinski, M.B.A. |
Chief Operating Officer |
-- |
08/01/2026 |
|
|
| Mr. Stuart A. Arbuckle |
Independent Director |
08/01/2026 |
| Mr. Marcio Souza |
Director, President and Chief Executive Officer |
19/02/2026 |
| Ms. Jill DeSimone |
Independent Director |
19/02/2026 |
| Dr. Jeffrey A. Chodakewitz, M.D. |
Independent Director |
19/02/2026 |
| Mr. Jeffrey B. Kindler, J.D. |
Independent Director |
08/01/2026 |
| Mr. William D. Young, PhD |
Independent Director |
19/02/2026 |
| Mr. Dean Jonathan Mitchell |
Chairman of the Board |
19/02/2026 |
| Mr. Gregory Norden |
Independent Director |
19/02/2026 |
| Dr. Merit Ester Cudkowicz, M.D. |
Independent Director |
19/02/2026 |
|
|
|
|
